677 611

Cited 11 times in

Diagnostic mutational analysis of MECP2 in Korean patients with Rett syndrome

DC Field Value Language
dc.contributor.author김흥동-
dc.date.accessioned2015-06-10T12:52:24Z-
dc.date.available2015-06-10T12:52:24Z-
dc.date.issued2006-
dc.identifier.issn1226-3613-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/110601-
dc.description.abstractRett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder affecting 1 per 10,000- 15,000 female births worldwide. The disease-causing gene has been identified as MECP2 (methyl- CpG-binding protein 2). In this study, we performed diagnostic mutational analysis of the MECP2 gene in RTT patients. Four exons and a putative promoter of the MECP2 gene were analyzed from the peripheral blood of 43 Korean patients with Rett syndrome by PCR-RFLP and direct sequencing. Mutations were detected in the MECP2 gene in approximately 60.5% of patients (26 cases/43 cases). The mutations consisted of 14 different types, including 9 missense mutations, 4 nonsense mutations and 1 frameshift mutation. Of these, three mutations (G161E, T311M, p385fsX409) were newly identified and were determined to be disease-causing mutations by PCR- RFLP and direct sequencing analysis. Most of the mutations were located within MBD (42.3%) and TRD (50%). T158M, R270X, and R306C mutations were identified at a high frequency. Additionally, an intronic SNP (IVS3+23C>G) was newly identified in three of the patients. IVS3+23C>G may be a disease-related and Korea-specific SNP for RTT. L100V and A201V are apparently disease-causing mutations in Korean RTT, contrary to previous studies. Disease-causing mutations and polymorphisms are important tools for diagnosing RTT in Koreans. The experimental procedures used in this study should be considered for clinical molecular biologic diagnosis.-
dc.description.statementOfResponsibilityopen-
dc.format.extent119~125-
dc.relation.isPartOfEXPERIMENTAL AND MOLECULAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHBase Sequence-
dc.subject.MESHDNA Mutational Analysis-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKorea-
dc.subject.MESHMale-
dc.subject.MESHMethyl-CpG-Binding Protein 2/genetics*-
dc.subject.MESHMolecular Sequence Data-
dc.subject.MESHMutation*-
dc.subject.MESHPolymerase Chain Reaction-
dc.subject.MESHPolymorphism, Restriction Fragment Length-
dc.subject.MESHPolymorphism, Single Nucleotide-
dc.subject.MESHRett Syndrome/diagnosis-
dc.subject.MESHRett Syndrome/genetics*-
dc.titleDiagnostic mutational analysis of MECP2 in Korean patients with Rett syndrome-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pediatrics (소아과학)-
dc.contributor.googleauthorIn-Joo Kim-
dc.contributor.googleauthorYeon-Joo Kim-
dc.contributor.googleauthorByeong-Hee Son-
dc.contributor.googleauthorSang-Ook Nam-
dc.contributor.googleauthorHoon-Chul Kang-
dc.contributor.googleauthorHeung-Dong Kim-
dc.contributor.googleauthorMi-Ae Yoo-
dc.contributor.googleauthorOok-Hwan Choi-
dc.contributor.googleauthorCheol-Min Kim-
dc.identifier.doi10.1038/emm.2006.15-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01208-
dc.relation.journalcodeJ00860-
dc.identifier.eissn2092-6413-
dc.identifier.pmid16672765-
dc.subject.keywordDNA mutational analysis diagnosis MECP2 protein-
dc.subject.keywordhuman-
dc.subject.keywordpolymorphism-
dc.subject.keywordrestriction fragment length-
dc.subject.keywordRett syndrome-
dc.contributor.alternativeNameKim, Heung Dong-
dc.contributor.affiliatedAuthorKim, Heung Dong-
dc.rights.accessRightsfree-
dc.citation.volume38-
dc.citation.number2-
dc.citation.startPage119-
dc.citation.endPage125-
dc.identifier.bibliographicCitationEXPERIMENTAL AND MOLECULAR MEDICINE, Vol.38(2) : 119-125, 2006-
dc.identifier.rimsid57155-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.